A Phase I/II Study of the HDAC Inhibitor LBH589 in Combination with the mTOR Inhibitor Everolimus (RAD001) in Metastatic Renal Cell Carcinoma

Phase I of this study will evaluate the safety and tolerability of three possible dose levels. The two drug regimen will be given as a three week cycle. A minimum of 6 patients will be treated at each dose level. Dose level toxicities will be evaluated to determine dose modifications and the recommended dose level for Phase II.
Phase II will evaluate the effects of this drug combination on the progression free survival in patients with metastatic RCC.

Study Number: 

I 146308

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.